These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28052002)

  • 1. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Rigaud VO; Ferreira LR; Ayub-Ferreira SM; Ávila MS; Brandão SM; Cruz FD; Santos MH; Cruz CB; Alves MS; Issa VS; Guimarães GV; Cunha-Neto E; Bocchi EA
    Oncotarget; 2017 Jan; 8(4):6994-7002. PubMed ID: 28052002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
    Qin X; Chang F; Wang Z; Jiang W
    Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
    Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Oliveira-Carvalho V; Ferreira LR; Bocchi EA
    J Appl Toxicol; 2015 Sep; 35(9):1071-2. PubMed ID: 26046768
    [No Abstract]   [Full Text] [Related]  

  • 5. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
    Todorova VK; Makhoul I; Wei J; Klimberg VS
    Ann Clin Lab Sci; 2017 Mar; 47(2):115-119. PubMed ID: 28442511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.
    Beaumier A; Robinson SR; Robinson N; Lopez KE; Meola DM; Barber LG; Bulmer BJ; Calvalido J; Rush JE; Yeri A; Das S; Yang VK
    J Vet Intern Med; 2020 May; 34(3):1260-1271. PubMed ID: 32255536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation.
    Alves MT; da Conceição IMCA; de Oliveira AN; Oliveira HHM; Soares CE; de Paula Sabino A; Silva LM; Simões R; Luizon MR; Gomes KB
    Cardiovasc Toxicol; 2022 Jul; 22(7):655-662. PubMed ID: 35524907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
    Lee M; Chung WB; Lee JE; Park CS; Park WC; Song BJ; Youn HJ
    Cancer Med; 2021 Jun; 10(12):3964-3973. PubMed ID: 33998163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
    Tashakori Beheshti A; Mostafavi Toroghi H; Hosseini G; Zarifian A; Homaei Shandiz F; Fazlinezhad A
    Cardiology; 2016; 134(1):47-53. PubMed ID: 26866364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats.
    Nishimura Y; Kondo C; Morikawa Y; Tonomura Y; Torii M; Yamate J; Uehara T
    J Appl Toxicol; 2015 Feb; 35(2):173-80. PubMed ID: 25092230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
    Ruggeri C; Gioffré S; Achilli F; Colombo GI; D'Alessandra Y
    Heart Fail Rev; 2018 Jan; 23(1):109-122. PubMed ID: 28944400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
    Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
    Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
    Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
    Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity.
    Holmgren G; Synnergren J; Andersson CX; Lindahl A; Sartipy P
    Toxicol In Vitro; 2016 Aug; 34():26-34. PubMed ID: 27033315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation.
    Wang E; Nie Y; Zhao Q; Wang W; Huang J; Liao Z; Zhang H; Hu S; Zheng Z
    J Cardiothorac Surg; 2013 Jul; 8():165. PubMed ID: 23816326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis.
    Pereira JD; Tosatti JAG; Simões R; Luizon MR; Gomes KB; Alves MT
    Biomed Pharmacother; 2020 Nov; 131():110709. PubMed ID: 32937248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.